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ABSTRACT
The in vitro antifungal activity of compounds 1-3 ({[CH3)2NCH2]2C6H3}R:SnX; (where X=CI, R=n-Bu
for 1, X=Br, R=n-Bu for 2 and x=PF6, R=n=Bu for 3)) was estimated with the help of a modified
microdilution format of the M27-A guidelines and was compared with in vitro activity of their
diphenyltin(IV) analogues 4 and 5 (where X=Br, R=Ph for 4 and X=PF6, R=Ph for 5), and of drugs currently
in clinical use (ketoconazole, fluconazole and amphotericin B). It was found that in coordinating solvents the
more soluble derivative 2 is less active than the phenyl one (4), and compounds and 3 are even inactive.
In this paper, the in vitro antitumour activity of ionic diphenyltin(IV) complexes 4 and 5 against seven
tumoural cell lines of human origin is also reported. The preparation and characterization (IH, l’C and lgsn
NMR spectroscopy and electrospray ionization mass spectrometry) of the novel compound 3 is mentioned
too.
INTRODUCTION
Organotin(IV) compounds, especially triorganotin derivatives, have been extensively studied due to their
potential in vitro antifungal activities against some medically important fungi/1/. Many compounds of this
type display some in vitro antitumour activities against tumour cell lines of human origin/2,3/. Moreover,
recently, Susperregui et al. have reported on in vivo trypanocidal activities of organotin(IV) compounds/4/.
In 1985 Atassi suggested that such in vivo antitumour activity and further clinical use of these compounds
in medicine could be hampered by low water solubility/5/. A possibility to increase the water solubility of
organotin compounds is to prepare compounds containing some heteroatoms in their structure/6/, or even
ionic compounds. We have previously reported on such ionic compounds (water solubility ca. 200 rag/100
ml/room temperature) and their in vitro antifungal activities. Some of these organotin derivatives display
MIC values (minimum inhibitory concentration tmol.I") comparable to those for currently used drugs/7/.
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We now present the results of in vitro antitumour screening for two selected diphenyltin(IV) complexes 4
and 5 and also the in vitro antifungal activity of their dibutyltin(IV) analogues 1-3.
EXPERIMENTAL
General comments and synthesis
All solvents were obtained frown commercial sources, dried by standard procedures and distilled prior to
use, Compounds l, 2, 4 and 5 (see Fig. l) were prepared according to literature procedure/7,8/.
[2,6-bis(dimethylaminomethyl)phenyl](di-n-butyl)stannylhexafluorophosphate 3" AKPF6 (0.36 g, 1.94
retool) was treated with a dichloromethane (200ml) solution of compound 2 (0.98 g, 1.94 retool). The
resulting suspension was stirred for 24 h at room temperature and then the insoluble material was filtered off,
the dichloromethane solution was evaporated in vacuo and the residue was crystallized from a chloroform/n-
pentane mixture (1:2), to give compound 3 as a pure white solid. Yield: 0.83 g (75%). M.p. 106-108C. Anal.
Calcd. for C2oHaTN2SnPF: C 42.20; H 6.55; N 4.92. Anal. Found: C 42.03; H 6.52; N 5.01. ttgsn NMR
(CDCla): t5 (ppm) 53.6. alp NMR (CDCI): t5 (ppm)-145.32 (septet, ij(31p, 19F) 713.4 Hz). 3C NMR
(CDCla): 8 (ppm) 133.89 (C(I), Ij(llgSn, taC)- not detected), 14.84 (C)(2, 6), 2J(llgsn, 13C) 32.6 Hz),
126.25 (C(3,5), 3j(ll9Srl, ISc) 56.2 Hz), 131.66 (C(4), 4j(ll9Srl, I3C) 9.2 Hz), 64.91 (NCH2, nj(llgsn, 13C)
29.1 Hz), 46.26 (N(CHs)2), 14.67 (C(I’), Ij(llgsrl, I3C) 413.4 Hz), 28.11 (C(2’) 2J(tgSn, 3C) 29.1 Hz),
26.84 (C(3’), 3J(tt9Sn, t3C) 90.9 Hz), 13.24 (H(4’). tH NMR (CDCI3): (ppm) 7.44 (t, IH, H(4)), 7.22 (d,
2H, H(3,5)), 3.80 (S, 4H, NCH2) 2.58 (s, 12H, N(CH3)2, 1.57 (m, 4H, H(I’)), 1.42 (m, h*, H(2’, 3’), 0.90 (t,
6H, H (4’)), ESI-MS: MW 570. Positive-ion MS" [M-PF6]+, m/z 425, 100%. Negative-ion MS: [PF6]-, m/z
145, 100%.
Spectra
The solution state llgsn, 3lp, 13C and tH NMR spectra were acquired at 134.28, 145.79, 90.56 and 360.13
MHz respectively, on a Bruker AMX 360 NMR spectrometer, using a 5 mm tuneable broad band probe at
300 K. Appropriate chemical shifts were calibrated on: tH-residual peak of CHCI3 ( 7.25 ppm), t3C.-signal
ofCDCla (5 77.0 ppm), atP-external 85% H3PO4 (t5 0.0 ppm) and t9Sn-external tetramethylstannane (t5
0.0 ppm).
Electrospray ionisation (ESI) mass spectra were measured on an ion trap analyser (Esquire 3000, Bruker
Daltonics) and on a quadrupole analyser (Platform, Micromass). The samples were dissolved in acetonitrile
and analysed by direct infusion at a flow rate of tl.min"t. Mass spectra weree recorded in the range m/z 15-
800, in both negative-ion and positive-ion mode.
In vitro antifungai screening
The in vitro testing was carried out using a modified microdilution broth of the M27-A guidelines
(National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal
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susceptibility testing of yeasts. Approved standard. Document M27-A, Wayne, PA: National Committee tbr
Clinical Laboratory Standards, 1997). Quality control strains (Candida albicans ATCC 90028, Candida
parapsilosis ATCC 22019, Candida krusei ATCC 6258) and amphotericin B, fluconazole (Pfizer),
ketoconazole (Janssen-Cilag, Beerse) as a reference drug were involved. All fungal strains were passaged on
Sabouraud dextrose agar at 35C prior to being tested.
The minimum inhibitory concentration (MIC) was determined by the following method: DMSO
(dimethylsulfoxide) served as a diluent for all compounds tested. DMSO did not exceed a final concentration
of 2%. RPMI 1640 (Sevapharma, Prague) medium, supplemented with L-glutamine and buffered with 0.165
M morpholinepropanesulfonic acid (Serva) to pH 7.0 (using l0 M NaOH), was used as a test medium. Each
well of the microdilution tray was filled with 200 gl of the RPMI 1640 medium with a diluted compound,
tested and then inoculated with 10 gl of suspension of a given fungal strain in sterile water. Fungal inoculum
was prepared to give a final size of 5 x 103 +/- 0.2 CFU ml"1. The trays were incubated at 35C and MICs read
after 24 and 48h. Owing to slow growth, the Trichophyton mentagrophytes strain was read at 72 and 120 h.
The MICs were determined visually and defined as 80% inhibition ofthe growth of control.
In vitro antitumour screening
The protocol followed for the in vitro antitumour screenings has already been reported/9/.
RESULTS AND DISCUSSION
Characterization and structure
Compounds 1, 2, 4 and 5 were previously investigated/7,8,10,1 l/by multinuclear NMR spectroscopy,
electrospray ionisation mass spectrometry and X-ray diffraction techniques. The identity and purity of all.
derivatives were verified by elemental analysis too.
R=nBu, X=CI
2 R=nBu, X=Br
3 R=nBu, X=PF6
4 R=Ph, X=Br
5 R=Ph, X=PF6
Fig. 1: Structure and numbering ofcompounds studied.
These compounds reveal the ionic structure with a five-coordinated tin atom and equivalent-
CHEN(CH3)2 groups (located in axial positions of a slightly distorted trigonal bipyramid) in solutions of
coordinating solvents.
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The compound 3 has been characterized with the help ofNMR spectra parameters which correspond to
appropriate ones in analogous above-mentioned compounds. One set of sharp signals was observed in the
proton spectrum measured in CDCI3 at room temperature, indicating equivalency of both amine donor and
butyl groups, respectively. The 9Sn chemical shift value (53.6 ppm) is comparable with previous results/8/
for ionic compounds (for example I and 2), from the range for five-coordinated (or better [3+2] tin atom in
ionic butyltin compounds. The extent of interatomic C(Bu)-Sn-C(Bu) angle can be calculated/12/from the
values of J(9Sn, 13C) coupling constant (413.4 Hz, 116.1). The symmetrical septet with lj(3p, 9F) 713.4
Hz in the 31p NMR spectrum shows that the PF6 group which does not interact with the tin atom is present.
On the basis of these findings, we can conclude that the vicinity of the tin central atom is slightly distorted
trigonal bipyramidal, with donor amino groups in axial and carbon atoms in equatorial positions, forming the
cationic unit. The hexafluorophosphate anion is out ofthe primary coordination sphere of the tin atom.
In vitro antifungal activity
The results of in vitro antifungal screening for all compounds 1-5 are summarized in Table together
with MIC values (minimum inhibitory concentration tmol"l) for conventional antimycotic drugs. The MICs
for derivatives 4,5 were reported earlier elsewhere/7/and are only used here for comparison of antimycotic
activity of their di-n-butyl analogues 1-3. The surprising discovery is that the bromobutyl derivative (2),
more soluble in coordinating solvents, is less active than the phenyl one, and compounds 1 and 3 are even
inactive.
Table 1
In vitro antifungal activity (MIC tmol ) ofcompounds studied, determined by microdilution broth method
MIC (lamol l’t)’’
t,
CG Compf TM CA CT CK TB
72h/120h 24h/48h 24h/48h 24h/48h 24h/48h 24h/48h
! 125/250 500/>500 250/500 >500/>500 >500/>500 >500/>500
2 31.25/62.5 7.8131.25 125/125 31.25/31.25 125/125 250/250
3 250/250
1.95/1.95
1.95/1.95
0.98/1.95
500/500
15.6/125
7.81/15.6
0.12/0.12
250/500 >500/>500
250/250
62.5/> 125
1.95/3.91
1.63/>417
7.81/15.6
3.91/7.81
3.91/3.91
d
>500/>500
125/250
15.6/125
0.240.98
>500/>500
>250/250
>125/125
0.12/0.24
3.26/6.53
AF AC
24h/48h 24h/48h
>500/>500 500/>500
62.5/125 62.5
>500/>500
7.81/15.6
250/>250
7.81/15.6
7.81/15.6 7.81/7.81
15.5/15.6 32.3/32.3
26.1/52.2 0.82/1.63 52.2/105 13.1/52.2 >417/417 >417/417
2.16/21.6 1.08/2.16 2.16/4.33 2.16/4.33 2.16/2.16 0.27/0.27 0.27/0.54 0.54/2.16
CA: Candida albicans ATCC 44895; TB: Trichosporon beigelii 1188; CT: Candida tropicalis 156; TM" T.
mentagrophytes 445; CK: Candida krusei E28; AF: Aspergillusfumigatus 231; CG: Candida glabrata 20/I;
AC: Absidia corymbifera 272.
The limit ofmaximum concentration tested of given compounds was given with its solubility in DMSO.
See Figure 1;
d Ketoconazole; Fluconazole;. ’Amphotericin B.
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In vitro antitumour activity
Compounds 4 and 5 were chosen for in vitro antitumour screening against seven tumoural cell lines of
human origin: MFC-7 and EVSA-T: two breast cancers; WiDr: a colon carcinoma; IGROV: an ovarian
cancer; M19MEL: a melanoma; A 498: a renal cancer and H 226: a non small cell lung cancer. The results of
in vitro tests, given in the form of IDs0 (the inhibition doses ng ml") for these two derivatives are shown in
Table 2 and compared with IDso values of some drugs with clinical applications. In spite of the fact that both
derivatives 4 and 5 display increased water solubility and promising in vitro antifungal activity/7/, Table 2
shows that both tested compounds are entirely inactive on all tumour cell lines.
Table 2
in vitro inhibition doses IDs0 in ng. ml" for compounds 4 and 5.
Compound
IDso (ng. ml’l)
MFC-7 EVSA-T WiDr IGROV M19MEL A 498 H 226
4 3460 3178 7538 8279 4420 7119 7903
$ 5018 3301 8998 9328 5161 8879 8742
cis.platin" 699 422 967 169 558 ..2...53 3269
d0xorubicine 10 8 11 60 16 90 [. 199.
et0P0side 2594 3 !.7 150 580 .505 1314 39.34
MFC-7 and EVSA-T: two breast cancers; WiDr: a colon carcinoma; IGROV" an ovarian cancer; M 19MEL:
a melanoma; A 498: a renal cancer and H 226: a non small cell lung cancer.
See Figure 1. IDa0 values taken from the literature, see/3/.
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